Please use this identifier to cite or link to this item: http://hdl.handle.net/11455/13457
標題: Acetaminophen與Ibuprofen對KK/HlJ肥胖小鼠血糖及組織鉻元素分佈之影響
Effects of Acetaminophen and Ibuprofen on Blood Glucose,Chromium Distribution in Obese KK/HlJ Mice
作者: 邱俊龍
Chiu, Chun-Lung
關鍵字: acetaminophen;鎮痛解熱劑;ibuprofen;obesity;blood glucose;chromium;肥胖;血糖;鉻元素
出版社: 獸醫學系暨研究所
引用: 1. Abbott FV and Hellemans KG (2000) Phenacetin, acetaminophen and dipyrone: Analgesic and rewarding effects. Behav Brain Res 112:177-186. 2. Anderson RA (1998) Chromium, glucose intolerance and diabetes. J Am Coll Nutr 17: 548-555. 3. Anderson RA, Cheng N, Bryden NA, Polansky MM, Chi J, Feng J (1997) Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. Diabetes 46:1786-1791. 4. Arner P, Pollare T, Lithell H, Livingston JN (1987) Defective insulin receptor tyrosine kinase in human skeletal muscle in obesity and type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 30: 437-440. 5. Bertolini A, Ferrari A, Ottani A, Guerzoni S, Tacchi R, Leone S (2006) Paracetamol: new vistas of an old drug. CNS Drug Rev 12:250-275. 6. Binkley JK, Eales J, Jekanowski M (2000) The relation between dietary change and rising US obesity. Int J Obes Relat Metab Disord 24:1032-1039. 7. Bjornholm M, Kawano Y, Lehtihet M, Zierath JR (1997) Insulin receptor substrate-1 phosphorylation and phosphatidylinositol 3-kinase activity in skeletal muscle from NIDDM subjects after in vivo insulin stimulation. Diabetes 46:524-527. 8. Bouchard C, Tremblay A, Despres JP, Nadeau A, Lupien PJ, Theriault G, Dussault J, Moorjani S, Pinault S, Fournier G (1990) The response to long-term overfeeding in identical twins. N Engl J Med 322:1477-1482. 9. Chang L, Chiang SH, Saltiel AR (2004) Insulin signaling and the regulation of glucose transport. Mol Med 10: 65-71. 10. Chen G, Liu P, Pattar GR, Tackett L, Bhonagiri P, Strawbridge AB, Elmendorf JS (2006) Chromium activates glucose transporter 4 trafficking and enhances insulin-stimulated glucose transport in 3T3-L1 adipocytes via a cholesterol-dependent mechanism. Mol Endocrinol 20: 857-870. 11. Chuang LM, Mao FC, Tai TY (2004) Effect of chromium chloride GTF milk powder supplement on gene expression of insulin signaling molecules in KK/HlJ diabetic mice. 25th Annual Meeting The Endocrinology Society & Diabetes Association of the Republic of China 89. 12. Clodfelder BJ, Upchurch RG, Vincent JB (2004) A comparison of the insulin-sensitive transport of chromium in healthy and model diabetic rats. J Inorg Biochem 98: 522-533. 13. Cusi K, Maezono K, Osman A, Pendergrass M, Patti ME, Pratipanawatr T, DeFronzo RA, Kahn CR, Mandarino LJ (2000) Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest 105:311-320. 14. Davis CM and Vincent JB (1997) Chromium oligopeptide activates insulin receptor tyrosine kinase activity. Biochemistry 36: 4382-4385. 15. Davis-Whitenack ML, Adeleye BO, Rolf LL, Stoecker BJ (1996) Biliary excretion of 51 chromium in bile-duck cannulated rats. Nutr Res 16: 1009-1015. 16. Deitel M (2003) Overweight and obesity worldwide now estimated to involve 1.7 billion people. Obes Surg 13: 329-330. 17. Flower RJ and Vane JR (1972) Inhibition of prostaglandin synthetase in brain explains the anti-pyretic activity of paracetamol (4-acetamidophenol). Nature 240:410-411. 18. Fuh CB, Lin HI, Tsai HY (2003) Determination of Lead, Cadmium, Chromium, and Arsenic in 13 Herbs of Tocolysis Formulation Using. Journal of Food and Drug Analysis 11: 39-45. 19. Gerdom LE and Goff HM (1982) Ligation modes for nicotinic acid binding to the chromium(III)salen complex. Inorg Chem 21: 3847-3848. 20. Guallar E, Jimenez FJ, van ''t Veer P, Bode P, Riemersma RA, Gomez-Aracena J, Kark JD, Arab L, Kok FJ, Martin-Moreno JM (2005) Low toenail chromium concentration and increased risk of nonfatal myocardial infarction. Am J Epidemiol 162: 157-164. 21. Heusner AA (1985) Body size and energy metabolism. Annu Rev Nutr 5: 267-293. 22. Hippisley CJ and Coupland C (2005) Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 330: 1366. 23. Hogestatt ED, Jonsson BAG, Ermund A (2005) Conversion of acetaminophen to the bioactive N-acylphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system. J Biol Chem 280:31405-31412. 24. Jacqz-Aigrain E and Anderson BJ (2006) Pain control: Non-steroidal anti-inflammatory agents. Seminars in fetal &neonatal medicine 11: 251-259. 25. Kahn SE, Hull RL, Utzschneider KM (2006) Mechanism linking obesity to insulin resistance and type 2 diabetes. Nature 444:840-846. 26. Khan S and Rupp J (1995). The effect of exercise conditioning, diet and drugtherapy on glycosylated hemoglobin levels in type 2 (NIDDM) diabetics. J Sports Med Phys Fitness 35: 281-288. 27. King JC (2000) Physiology of pregnancy and nutrient metabolism. Am J Clin Nutr May 71: 1218-1225. 28. Kopelman PG (2000) Obesity as a medical problem. Nature 404: 635-643. 29. Krook A, Bjornholm M, Galuska D, Jiang XJ, Fahlman R, Myers MG Jr, Wallberg-Henriksson H, Zierath JR (2000) Characterization of signal transduction and glucose transport in skeletal muscle from type 2 diabetic patients. Diabetes 49:284-292. 30. Krook A, Roth RA, Jiang XJ, Zierath JR, Wallberg-Henriksson H (1998) Insulin-stimulated Akt kinase activity is reduced in skeletal muscle from NIDDM subjects. Diabetes 47:1281-1286. 31. Lamson DS and Plaza SM (2002) The safety and efficacy of high-dose chromium. Altern Med Rev 7: 218-235. 32. Lukaski HC (1999) Chromium as a supplement. Annu Rev Nutr 9: 279-302. 33. Machalinski B, Walczak M, Syrenicz A, Machalinska A, Grymula K, Stecewicz I, Wiszniewska B, Dabkowska E (2006) Hypoglycemic potency of novel trivalent chromium in hyperglycemic insulin-deficient rats. J Trace Elem Med Biol 20: 33-39. 34. Martin J, Wang ZQ, Zhang XH, Wachtel D, Volaufova J, Matthews DE, Cefalu WT (2006) Chromium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with type 2 diabetes. Diabetes Care 29:1826-1832. 35. Mertz W, Toepfer EW, Roginski EE, Polansky MM (1974) Present knowledge of the role of chromium. Fed Proc 33: 2275-2280. 36. Morris BW, Gray TA, Macneil S (1993) Glucose-dependent uptake of chromium in human and rat insulin-sensitive tissues. Clin Sci (Lond) 84: 477-482. 37. Morris BW, Griffiths H, Kemp GJ (1988) Correlations between abnormalities in chromium and glucose metabolism in a group of diabetics. Clin Chem 34: 1525-1526. 38. Morse HN (1878) Ueber eine neue Darstellungsmethode der Acetylamidophenole. Ber Deutscher Chem Ges 11:232-233. 39. Nielsen FH (1994) Chromium. In: Shils ME, Olson JA, Shike M.,eds.Mondern nutrition in health and disease. Philadelphia: Lea and Febiger 264-268. 40. Ottani A, Leone S, Sandrini M (2006) The analgesic activity of paracetamol is prevented by the blockade of cannabinoid CB1 receptors. Eur J Pharmacol 531:280-281. 41. Perusse L, Rankinen T, Zuberi A, Chagnon YC, Weisnagel SJ, Argyropoulos G, Walts B, Snyder EE, Bouchard C (2005) The human obesity gene map: the 2004 update. Obes Res 13:381-490. 42. Pessin JE and Saltiel AR (2001) Signaling pathways in insulin action: molecular targets of insulin resistance. J Clin Invest 2000 Jul 106: 165-169. 43. Rang HP, Dale MM, Ritter JM, Moore PK (2003) Pharmacology, 5th Edition. Kidlington, Oxford: Elsevier Ltd. 44. Rice T, Tremblay A, Deriaz O, Perusse L, Rao DC, Bouchard C (1996) A major gene for resting metabolic rate unassociated with body composition: results from the Quebec Family Study. Obes Res 4:441-449. 45. Rubin MA, Miller JP, Ryan AS, Treuth MS, Patterson KY, Pratley RE, Hurley BF, Veillon C, Moser-Veillon PB, Anderson RA (1998) Acute and chronic resistive exercise increase urinary chromium excretion in men as measured with an enriched chromium stable isotope. J Nutr Jan 128: 73-78. 46. Saltiel AR and Kahn CR (2001) Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414: 799-806. 47. Shankar K, Vaidya VS, Apte UM, Manautou JE, Ronis MJ, Bucci TJ, Mehendale HM (2003) Type 1 diabetic mice are protected from acetaminophen hepatotoxicity. Toxicol Sci. 73(2):220-34. 48. Sharma AM (2006) The obese patient with diabetes mellitus: from research targets to treatment options. Am J Med 119: 17-23. 49. Shinde Urmila A, Sharma G, Xu Yan J, Dhalla Naranjan S, Goyal Ramesh K (2004) Anti-diabetic activity and mechanism of action of chromium chloride. Exp Clin Endocrinol Diabetes 112: 248-252. 50. Skoglund LA, Skjelbred P, Fyllingen G (1991) Analgesic efficacy of acetaminophen 1000 mg, acetaminophen 2000 mg, and the combination of acetaminophen 1000 mg and codeine phosphate 60 mg versus placebo in acute postoperative pain. Pharmacotherapy 11:364-369. 51. Stearns DM (2000) Is chromium a trace essential metal? Biofactors 11: 149-162. 52. Stoecker BJ. (1990) Chromium. In: Brown ML, ed. Present knowledge in nutrition. International Life Sciences Institute Nutrition Foundation. Washington, USA. 287-293. 53. Townsend KP and Praticò D (2005) Novel therapeutic opportunities for Alzheimer''s disease: focus on nonsteroidal anti-inflammatory drugs. FASEB J 19:1592-1601. 54. Tuman RW, Bilbo JT, Doisy RJ (1978) Comparison and effects of natural and synthetic glucose tolerance factor in normal and genetically diabetic mice. Diabetes 27: 49-56. 55. Tuman RW and Doisy RJ (1977) Metabolic effects of the glucose tolerance factor (GTF) in normal and genetically diabetic mice. Diabetes 26: 820-826. 56. Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 23:232-235. 57. Vrtovec M, Vrtovec B, Briski A, Kocijancic A, Anderson RA, Radovancevic B (2005) Chromium supplementation shortens QTc interval duration in patients with type 2 diabetes mellitus. Am Heart J 149: 632-636. 58. Vincent JB (2000) The biochemistry of chromium. J Nutr 130: 715-718. 59. Volpe SL, Huang HW, Larpadisorn K, Lesser II (2001) Effect of chromium supplementation and exercise on body composition, resting metabolic rate and selected biochemical parameters in moderately obese women following an exercise program. J Am Coll Nutr 20: 293-306. 60. Von Mering J (1893) Beitrage zur Kenntniss der Antipyretica. Ther Monatsch 7:577-587. 61. Wang H, Kruszewski A, Brautigan DL (2005) Cellular chromium enhances activation of insulin receptor kinase. Biochemistry 44:8167-8175. 62. Yach D, Stuckler D, Brownell KD (2006) Epidemiologic and economic consequences of the global epidemics of obesity and diabetes. Nat Med 12:62-66. 63. Yamamoto A, Wada O, Ono T. (1987) Isolation of a biologically active low-molecular-mass chromium compound from rabbit liver. Eur J Biochem. 165: 627-631. 64. Yamamoto A, Wada O, Suzuki H (1988) Purification and properties of biologically active chromium complex from bovine colostrum. J Nutr Jan 118: 39-45. 65. Yang X, Palanichamy K, Ontko AC, Rao MN, Fang CX, Ren J, Sreejayan N (2005) A newly synthetic chromium complex--chromium(phenylalanine)3 improves insulin responsiveness and reduces whole body glucose tolerance. FEBS Lett 579: 1458-1464. 66. Zimmet P, Alberti KG, Shaw J (2001) Global and societal implications of the diabetes epidemic. Nature 414: 782-787.
摘要: 
Acetaminophen (APAP)及ibuprofen是目前廣泛被使用的鎮痛解熱劑,作用機轉為抑制生物體環氧化酶,阻斷前列腺素的生成。而近來文獻指出抑制第二型環氧化酶的活性和胰島素敏感性的增加呈正相關。本研究目的為探討KK/HlJ品系肥胖小鼠使用APAP及ibuprofen後,其體內血糖、組織中協助葡萄糖代謝之鉻元素含量及血清中胰島素濃度的變化。實驗將KK/HlJ小鼠分別餵食標準飼料 (Normal Diet, ND)及高油脂飼料(High-Fat Diet, HFD),四週後依餵飼飼料種類再各分成三組,於腹腔注射生理食鹽水、APAP (200 mg/kg)及ibuprofen (100 mg/kg),3小時後犧牲小鼠檢測血糖值並分析各組織中鉻元素含量及血清中胰島素濃度。結果顯示HFD組的禁食體重顯著高於ND組 (38.9 vs. 36.4 g, P<0.01),腹腔脂肪含量HFD組顯著高於ND組 (4.62 vs. 2.93 g, P<0.001)。注射APAP後HFD組的血糖值顯著低於ND組 (64 vs. 130 mg/dl, P<0.01),注射ibuprofen後血糖值則無顯著變化。分析組織中鉻元素含量顯示,HFD組肝臟鉻元素含量顯著低於ND組(p<0.001),其餘組織亦有減少的趨勢。注射APAP後,HFD組肝臟鉻元素含量上升65%,ND組則無顯著變化。注射ibuprofen後,HFD組及ND組肝臟鉻元素含量均無顯著變化。血清中胰島素濃度,HFD組有低於ND組的趨勢(p<0.1)。綜合上述實驗結果顯示,KK/HlJ小鼠以高脂飲食誘導肥胖模式可成功誘發小鼠肥胖並使組織中鉻元素含量減少。肥胖會造成KK/HlJ小鼠注射APAP後肝臟鉻元素的移動幅度變大及血糖顯著降低,推測會造成個體血糖控制的惡化,而ibuprofen則無此現象。

Acetaminophen (APAP) and ibuprofen are the most common analgesic and antipyretic agents. Both drugs act by reducing prostaglandin biosynthesis through inhibition of cyclooxygenase (COX) enzymes. Recent studies implicate that inhibition of the COX-2 activation would enhance the insulin sensitivity in normal and obese subjects with type 2 diabetes. KK/HlJ mice are inheritantly glucose intolerant with insulin resistance, and develop overt diabetes if they become obese due to dietary manipulation or aging. The aim of this study was designed to evaluate the effects of APAP and ibuprofen on blood glucose concentration and chromium distribution in normal and obese KK/HlJ mice. Mice aged 15 weeks were randomly assigned to two groups with normal diet (ND) or high-fat diet (HFD) for 4 weeks and subsequently the mice in each group were further divided into three subgroups (n=6/group) treated with APAP (200 mg/kg), ibuprofen (100 mg/kg) and saline. The results of this study indicated that fasting body weight, blood glucose and visceral fat were significantly increased, but chromium content and serum insulin level decreased in HFD group. Blood glucose concentration of HFD group were significantly less than ND group after APAP treatment. It had no significantly difference among two groups after ibuprofen treatment.
URI: http://hdl.handle.net/11455/13457
其他識別: U0005-2708200716132300
Appears in Collections:獸醫學系所

Show full item record
 

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.